A2B adenosine receptor antagonists
View Patent ↗Disclosed are novel A 2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
1. A compound of the Formula I or Formula II:
wherein:
R 1 and R 2 are independently chosen from hydrogen, optionally substituted alkyl, or a group -D-E, in which D is a covalent bond or alkylene, and B is optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkenyl, or optionally substituted alkynyl, with the proviso that when D is a covalent bond E cannot be alkoxy;
R 3 is hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl;
X is optionally substituted pyrazolene that is attached to the purine ring at a carbon atom;
Y is alkylene in which one carbon atom can be optionally replaced by —O—, —S—, or —NH—, and is optionally substituted by hydroxy, alkoxy, optionally substituted amino, or —COR, in which R is hydroxy, alkoxy or amino;
with the proviso that when the optional substitution is hydroxy or amino said substitution cannot be present on a carbon atom that is adjacent to a heteroatom; and
Z is optionally substituted monocyclic aryl or optionally substituted monocyclic heteroaryl.
2. The compound of claim 1 , wherein:
R 1 and R 2 are independently hydrogen or optionally substituted lower alkyl,
R 3 is hydrogen; and
Y is lower alkylene.
3. The compound of claim 2 , wherein Z is optionally substituted phenyl, optionally substituted oxadiazolyl, optionally substituted isoxazolyl, or optionally substituted pyridyl.
4. The compound of claim 3 , wherein R 1 is lower alkyl optionally substituted by cycloalkyl and R 2 is hydrogen.
5. The compound of claim 4 , wherein X is optionally substituted 1,4-pyrazolene.
6. The compound of claim 5 , wherein Y is —CH 2 —, and Z is optionally substituted phenyl.
7. The compound of claim 5 , wherein Y is —CH 2 —, and Z is optionally substituted oxadiazolyl.
8. The compound of claim 5 , wherein Y is —CH 2 —, and Z is optionally substituted pyridyl.
9. The compound of claim 8 , wherein R 1 is cyclopropylmethyl, X is 1,4-pyrazolene, Y is —CH 2 —, and Z is 2-pyridyl, namely 1-(cyclopropylmethyl)-8-[1-(2-pyridylmethyl)pyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione.
10. The compound of claim 8 , wherein R 1 is n-butyl, X is 1,4-pyrazolene, Y is —CH 2 —, and Z is 3-trifluoromethylpyrid-2-yl, namelyl-n-butyl-8-[1-(6-trifluoromethylpyridin-3-ylmethyl)pyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione.
11. The compound of claim 3 , wherein R 1 and R 2 are independently lower alkyl optionally substituted by cycloalkyl.
12. The compound of claim 11 , wherein X is optionally substituted 1,4-pyrazolene and Y is —CH 2 — or —CH(CH 3 )—.
13. The compound of claim 12 , wherein R 1 and R 2 are n-propyl, Y is —CH 2 —, and Z is 3-(4-chlorophenyl) [1,2,4]oxadiazol-5-yl, namely 8-(1-{[3-(4-chlorophenyl)(1,2,4-oxadiazol-5-yl)]methyl}pyrazol-4-yl)-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione.
14. The compound of claim 12 , wherein R 1 and R 2 are n-propyl, Y is —CH 2 —, and Z is 5-(4-trifluoromethylphenyl)isoxazol-3-yl, namely 1,3-dipropyl-8-[1-({5-[4-(trifluoromethyl)phenyl]isoxazol-3-yl}methyl)pyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione.
15. The compound of claim 12 , wherein R 1 and R 2 are n-propyl, Y is —CH 2 —, and Z is pyrid-2-yl, namely 1,3-dipropyl-8-[1-(2-pyridylmethyl)pyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione.
16. The compound of claim 12 , wherein R 1 and R 2 are n-propyl, Y is —CH 2 —, and Z is 3-carboxyphenyl, namely 3-{[4-(2,6-dioxo-1,3-dipropyl-1,3,7-trihydropurin-8-yl)pyrazolyl]methyl}benzoic acid.
17. The compound of claim 12 , wherein R 1 and R 2 are n-propyl, Y is —CH 2 —, and Z is 2-trifluoromethylpyrid-3-yl, namely 1,3-dipropyl-8-(1-{[6-(trifluoromethyl)(3-pyridyl)]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione.
18. The compound of claim 12 , wherein R 1 and R 2 are n-propyl, Y is —CH 2 —, and Z is 3-(1,2,3,4-tetrazol-5-yl)phenyl, namely 1,3-dipropyl-8-{1-[(3-(1H-1,2,3,4-tetraazol-5-yl)phenyl)methyl]pyrazol-4-yl}-1,3,7-trihydropurine-2,6-dione.
19. The compound of claim 12 , wherein R 1 and R 2 are n-propyl, Y is —CH 2 —, and Z is 6-carboxy-pyrid-2-yl, namely 6-{[4-(2,6-dioxo-1,3-dipropyl-1,3,7-trihydropurin-8-yl)pyrazolyl]methyl}pyridine-2-carboxylic acid.
20. The compound of claim 12 , wherein R 1 is n-propyl, R 2 is ethyl, Y is —CH 2 —, and Z is 2-pyridyl, namely 3-ethyl-1-propyl-8-[1-(2-pyridylmethyl)pyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione.
21. The compound of claim 12 , wherein R 1 is n-propyl, R 2 is ethyl, Y is —CH 2 —, and Z is 5-(4-chlorophenyl)-isoxazol-3-yl, namely 8-(1-{[5-(4-chlorophenyl)isoxazol-3-yl]methyl}pyrazol-4-yl)-3-ethyl-1-propyl-1,3,7-trihydropurine-2,6-dione.
22. The compound of claim 12 , wherein R 1 is n-propyl, R 2 is ethyl, Y is —CH 2 —, and Z is 3-(4-chlorophenyl)-[1,2,4]-oxadiazol-5-yl, namely 8-(1-{[3-(4-chlorophenyl)(1,2,4-oxadiazol-5-yl)]methyl}pyrazol-4-yl)-3-ethyl-1-propyl-1,3,7-trihydropurine-2,6-dione.
23. The compound of claim 12 , wherein R 1 is n-propyl, R 2 is ethyl, Y is —CH 2 —, and Z is 6-(trifluoromethyl)-pyrid-3-yl, namely 3-ethyl-1-propyl-8-(1-{[6-(trifluoromethyl)(3-pyridyl)]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione.
24. The compound of claim 12 , wherein R 1 is cyclopropylmethyl, R 2 is ethyl, Y is —CH 2 —, and Z is 6-(trifluoromethyl)-pyrid-3-yl, namely 1-(cyclopropylmethyl)-3-ethyl-8-(1-{[6-(trifluoromethyl)(3-pyridyl)]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione.
25. The compound of claim 12 , wherein R 1 is 2-methylpropyl, R 2 is ethyl, Y is —CH 2 —, and Z is 6-(trifluoromethyl)-pyrid-3-yl, namely 3-ethyl-1-(2-methylpropyl)-8-(1-{[6-(trifluoromethyl)(3-pyridyl)]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione.